“SkyQuest Technology Group has recently published a comprehensive Biomarkers Market report, offering a detailed analysis of the product landscape and industry scope while providing insights into the market outlook and future trends from 2025 to 2032. The biomarker market is expanding strongly with expanding uses in diagnostics, drug development, and targeted treatment. Biomarkers also play a crucial role in the early diagnosis of disease, disease prognosis, and monitoring of treatment response and are valuable assets in many therapeutic fields like oncology, neurology, and cardiology.
Global Biomarkers Market size was valued at USD 58.2 billion in 2023 and is poised to grow from USD 65.36 billion in 2024 to USD 165.33 billion by 2032, growing at a CAGR of 12.3% during the forecast period (2025-2032).
Advancements in genomics, proteomics, and bioinformatics technology are assisting in the identification and validation of biomarkers and thus their prospect for application in the clinic. Pharmaceutical and biotech organizations are to a great degree enabled by biomarker-based research to find drugs and attain regulatory approval. Furthermore, increased adoption of companion diagnostics and biomarkers for clinical trials is also driving Biomarkers Market growth. As the health care sector is gearing up for precision medicine, global demand for precise, non-invasive, and predictive biomarkers is increasing. Biomarkers market drivers are increasing incidence rates for chronic diseases like cancer, diabetes, and cardiovascular disease.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/biomarkers-market
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Biomarkers Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
The global biomarkers market is segmented by Product, Type, Research Area, Technology, Disease Indication, Application, End User and region.
Based on Product, the market is segmented into Consumables, Services and Software.
Based on Type, the market is segmented into Safety Biomarkers, Efficacy Biomarkers and Validation Biomarkers.
Based on Research Area, the market is segmented into Genomics, Proteomics, Metabolomics and Others.
Based on Technology, the market is segmented into Immunoassays, Ngs, Pcr, Mass Spectrometry, Chromatography and Others.
Based on Disease Indication, the market is segmented into Cancer, Infectious Diseases, Immunological Disorders, Neurological Disorders, Cardiovascular Disorders and Others.
Based on Application, the market is segmented into Clinical Diagnostics, Drug Discovery & Development, Personalized Medicine, Clinical Research and Others.
Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Academic & Research Institutes and Others.
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Biomarkers Market – Regional Analysis:
North America dominates the world biomarkers market with strong healthcare infrastructure, high R&D spending, and rampant incidence of chronic diseases. The U.S. market alone would be valued at USD 124.49 billion by 2034 with a CAGR of 15.22%. The drivers on their list are genomics, proteomics, and bioinformatics advances, which would facilitate the discovery of new biomarkers. Government programs such as the Cancer Moonshot and Precision Medicine Initiative propel market growth by investing in biomarker R&D.
Canada biomarker market is growing with sufficient healthcare and government support. Canadian Institutes of Health Research (CIHR) initiatives fund biomarker research that leads to innovation. Biotechnology companies and Canadian universities drive the expansion of personalized medicine through collaboration. Sharing and integration of data enable large-scale biomarker studies in Canada, which could be a future global leader in the biomarkers market.
Europe maintains a large share of the total biomarkers market, seconded by Germany, France, and the United Kingdom. Germany will have a CAGR of 14.6% to reach USD 18.1 billion by 2030. The UK will also grow steadily backed by improved precision medicine, increasing spending in healthcare, and attention to personalized treatments.
Top Market Players in Biomarkers Market are:
F. Hoffmann-La Roche Ltd
Abbott
Agilent Technologies
Bio-Rad Laboratories
Bruker
Charles River Laboratories
CENTOGENE
Enzo Biochem
Epigenomics
Eurofins Scientific
EKF Diagnostics Holdings
GE Healthcare
Illumina, Inc.
Merck
MESO SCALE DIAGNOSTICS
Charles River Laboratories
Johnson & Johnson Services, Inc.
PerkinElmer
Siemens Healthineers
QIAGEN
Sino Biological
Thermo Fisher Scientific
Recent Developments in Biomarkers Market:
In June 2025, Quanterix Corporation’s HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device approval in South Korea, enabling expanded use of its ultrasensitive biomarker detection technology for Alzheimer’s disease diagnosis. This approval, achieved through local distributor HS Biosystems, marks a key step in advancing early detection capabilities and increasing access to minimally invasive diagnostics in global markets.
In June 2025, Researchers have developed a novel, non-invasive screening method that detects Parkinson’s disease by analyzing volatile organic compounds (VOCs) in ear wax. This AI-powered olfactory system demonstrated 94% accuracy in distinguishing Parkinson’s from non-Parkinson’s samples. The method offers a cost-effective approach to early diagnosis and could significantly improve intervention strategies in neurodegenerative disease management.
In March 2025, Researchers showcased a multimodal AI-based biomarker model for early detection of cancer cachexia. Laying the foundation of patient demographics, lab values, radiological findings, and clinical documentation, the model offers a cost-effective means to detect cachexia at cancer diagnosis time, allowing for personalized therapy and better patient outcomes.
You may Also Like
https://www.skyquestt.com/report/water-soluble-fertilizer-market
https://issuu.com/skyquest-technology/docs/smart_energy_market_investment_insights_and_future
Forward-Looking Insights
The Biomarkers Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]”
